Skip to Content
Søk Menu

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

The DESTINY-Breast11 trial showed that anthracycline-free T-DXd-THP improved response rates and safety compared with standard therapy in high-risk HER2-positive early breast cancer.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Katarina Puco

ESMO 2025: Precision Medicine Trial Shows Promise in Rare Cancers

/ Katarina Puco
ESMO25 Play the Video 01:56

ESMO 2025: Advancements to improve patient outcomes and quality of life in Immunotherapy

/ Christina Ruhlmann
ESMO25 Play the Video 4:45

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
ESMO25 Play the Video 04:57

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Jan Andreasen
ESMO25Prostatacancer

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

/ Danny Rischin
ESMO25Hudcancer Play the Video 03:46

ESMO 2025: The Future of Oncology Will Be Built by Individuals

/ Jan Andreasen
ESMO25

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
BröstcancerESMO25
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
Bröstcancer Play the Video 06:19
Dimitrios Salgkamis

ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

/ Dimitrios Salgkamis
BröstcancerNBCN Play the Video 05:35
Back to top